- BioDuro and Atombeat have announced a strategic collaboration to develop an AI-powered platform for peptide drug discovery.
- The partnership integrates Atombeat’s in silico modeling tools with BioDuro’s peptide synthesis and biology capabilities to speed up early-stage R&D.
BioDuro, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has formed a strategic partnership with Atombeat Inc., a specialist in AI-driven drug discovery. The companies will collaborate to develop an AI-powered platform designed to accelerate peptide drug discovery across therapeutic areas.
The alliance brings together Atombeat’s proprietary Hermite® software and RiDYMO® platform with BioDuro’s expertise in discovery chemistry, biology, and DMPK. The integrated solution aims to provide an end-to-end workflow from molecular design through to preclinical candidate selection.
Atombeat’s technologies allow researchers to model and evaluate over a trillion peptide compounds in silico before any lab testing begins. These are filtered based on developability traits such as membrane permeability, helping to reduce the time and cost associated with early-stage discovery. BioDuro then applies its high-throughput synthesis capabilities to produce peptide compounds rapidly, often within a week and without requiring purification.
“We are excited to advance peptide innovation through our strategic partnership with Atombeat,” said Dr. Armin Spura, CEO of BioDuro. “Together, we aim to provide the industry with leading services in peptide drug development.”
The platform is intended to deliver high-quality cyclic peptides at a faster pace and improved cost efficiency, addressing unmet clinical needs through smarter and more integrated drug development processes.
